X-Ray Crystallographic and Kinetic Analysis of Human Purine Nucleoside Phosphorylase Complexes with 1-β-D-Ribofuranosyl-1,2,4-triazole-3-carobxamide and 1-β-D-Ribofuranosyl-1,2,4-triazole-3-carboxamidine
- 1 March 1994
- journal article
- research article
- Published by Taylor & Francis in Nucleosides and Nucleotides
- Vol. 13 (1) , 689-706
- https://doi.org/10.1080/15257779408013273
Abstract
The three-dimensional structures of the complexes between human erythrocytic purine nucleoside phosphorylase (PNP) and both 1-β-D-ribofuranosyl-1,2,4-triazole-3-carboxamide (ribavirin) and 1-β-D-ribofuranosyl-1,2,4-triazole-3-carboxamidine (TCNR) have been determined using X-ray crystallographic techniques. The structures have been refined at 2.9 Å resolution using simulated annealing and conjugate-gradient minimization techniques to an R value of 21.8% for ribavirin and 20.8% for TCNR. Ribavirin and TCNR are truncated nucleosides corresponding to adenosine and inosine, respectively, and are of potential interest as PNP inhibitors. Kinetic parameters have been determined for recombinant wild-type PNP and for a mutant PNP in which Asn 243 is converted to Asp. The Ki value for ribavirin is 4.9 mM with wild-type PNP and 4.7 mM with the Asn243Asp mutant, while the Ki values for TCNR are 17.6 μM and 3.8 μM with wild-type and mutant, respectively. X-ray crystallographic studies showed that the binding geometry for both of these substrate analogues was similar to that seen for natural substrates. The glycosidic torsion angles (χ) were −34° for ribavirin and −39° for TCNR which are in good agreement with values seen for other studied nucleoside complexes with PNP, but which are unusual when compared to those seen for free nucleic acid derivatives. Based upon the three-dimensional structure, interactions of Asn 243 and Glu 201 with a protonated carboxamidine of TCNR explain the stronger inhibition of PNP observed for TCNR over ribavirin.Keywords
This publication has 12 references indexed in Scilit:
- Application of crystallographic and modeling methods in the design of purine nucleoside phosphorylase inhibitors.Proceedings of the National Academy of Sciences, 1991
- Three-dimensional structure of human erythrocytic purine nucleoside phosphorylase at 3.2 A resolution.Journal of Biological Chemistry, 1990
- CHAIN — A crystallographic modeling programJournal of Molecular Graphics, 1988
- Synthesis and evaluation of 5-amino-1-.beta.-D-ribofuranosyl-1,2,4-triazole-3-carboxamidine and certain related nucleosides as inhibitors of purine nucleoside phosphorylaseJournal of Medicinal Chemistry, 1988
- Ribavirin: An antiviral agentPharmacology & Therapeutics, 1979
- The crystal and molecular structures of two polymorphic crystalline forms of virazole (1-β-D-ribofuranosyl-1,2,4-triazole-3-carboxamide). A new synthetic broad sprectrum antiviral agentActa Crystallographica Section B: Structural Science, Crystal Engineering and Materials, 1976
- Synthesis of nucleosides of 5‐substituted‐1,2,4‐triazole‐3‐carboxamidesJournal of Heterocyclic Chemistry, 1974
- Synthesis and antiviral activity of 1,2,4-triazole-3-thiocarboxamide and 1,2,4-triazole-3-carboxamidine ribonucleosidesJournal of Medicinal Chemistry, 1973
- Design, synthesis, and broad spectrum antiviral activity of 1-.beta.-D-ribofuranosyl-1,2,4-triazole-3-carboxamide and related nucleosidesJournal of Medicinal Chemistry, 1972
- Broad-Spectrum Antiviral Activity of Virazole: 1-β-D-Ribofuranosyl-1,2,4-triazole-3-carboxamideScience, 1972